VivoLight Medical Secures RMB 120 Million in Funding to Advance Cardiovascular Imaging and Interventional Devices

VCBeat (WeChat ID: vcbeat) has learned that MicroLight Medical recently announced the completion of a financing round exceeding RMB 120 million, led by Tus-Holdings Science & Technology Services and co-invested by Xi’an High-Tech Investment Group. The funds from this round will be primarily used for the development of new products in interventional image-guided therapy and the construction of its Silk Road headquarters base in Xi’an.

According to data from the American Heart Association, cardiovascular disease ranks as the leading cause of death globally, claiming 17.9 million lives each year—equivalent to one death every two seconds. The global annual economic burden of cardiovascular disease amounts to approximately $900 billion. In China’s rapidly expanding medical device market, cardiac-related products are experiencing the most significant growth rate.

Weiguang Medical has been dedicated to innovating imaging devices for cardiovascular interventional procedures, boasting over a decade of technical expertise in laser medicine and interventional devices. The company launched China’s first clinical-grade cardiovascular Optical Coherence Tomography (OCT) system and venous visualization instrument, and has established long-term strategic partnerships with the Chinese Academy of Sciences, the PLA General Hospital, and Harvard Medical School. Currently, multiple products have entered the registration application and clinical trial stages. Its flagship cardiovascular OCT device aims to address the lack of precise imaging in cardiac surgeries within the Chinese market, vigorously promoting the domestic production of high-end medical imaging equipment.

Weiguang Medical's Cardiovascular 3D-OCT System and Surgical Guidance Interface

Amid the current tight capital market and cautious investment climate, Weiguang Medical’s securing of hundreds of millions in financing clearly demonstrates investors’ confidence in its technology and team strength. Zhu Rui, founder of Weiguang Medical, stated that the participation of Tus-Holdings Science & Technology Services and Xi’an High-Tech Investment Group provides strong support for advancing the interventional device industry and regional strategic layout, while further bolstering the team’s resilience to navigate economic challenges. Currently, clinical trials for Weiguang Medical’s flagship product have been successfully completed, and multiple other intravascular imaging and interventional therapy products under development are progressing as scheduled. Construction of the company’s Silk Road headquarters in Xi’an is set to commence, with formal operation expected by June 2019.

“We are highly optimistic about Weiguang Medical and will support its development into a leading Chinese enterprise in the field of cardiovascular interventional imaging.” Regarding the capital injection from its affiliated funds, He Huanrong, Vice President of Tus-Holdings Science & Technology Services, stated, “The high-value medical device sector, characterized by significant penetration and application of emerging cardiac technologies, is a key focus of our investment strategy. The Weiguang Medical team possesses extensive research experience in Optical Coherence Tomography (OCT), has expertise in developing internationally advanced interventional imaging technologies, and understands the demands of the domestic clinical market. This cardiovascular imaging system enables operators to visually assess the nature of intravascular thrombi, which is expected to significantly enhance the safety of clinical procedures and reduce the overuse of coronary stents in the future.”